期刊文献+

护理干预对奥氮平致代谢综合征患者的影响 被引量:12

The effect of nursing intervention on metabolic syndrome caused by Olanzapine
原文传递
导出
摘要 目的探讨采用奥氮平治疗精神分裂症患者时护理干预对奥氮平致代谢综合征的影响。方法将单用奥氮平治疗的首发精神分裂症患者100例,随机分为干预组和对照组各50例。对照组进行常规精神病护理,干预组增加预防代谢综合征的护理干预措施。分别在入院当日及人院后第4、8、12、48周比较2组体重指数、空腹血糖、三酰甘油、胆固醇、高密度脂蛋白的变化。结果干预组在第4周体重指数与空腹血糖、三酰甘油、胆固醇显著低于对照组,高密度脂蛋白高于对照组。结论加强护理干预措施,可以有效控制奥氮平治疗引起的代谢综合征,以提高患者服药依从性,预防精神分裂症复发。 Objective To study the influence of nursing intervention on metabolisyndrome of schizophrenipatienttreated with Olanzapine. Method100 acuteepisode schizophrenipatienttreated with Olanzapine alone were randomized into the intervention group and the control group, each group with 50 cases. The control group received the routine psychiatrinursing, and the intervention group added nursing intervention to prevenmetabolisyndrome. The changeof BMI, fasting blood-glucose, triglyceride, cholesterol, high- density lipoprotein of both groupwere compared on the day upon admission and on the 4th, 8th, 12th and 48th weekaftehospitalization respectively. ResultOn the 4th week BMI and fasting blood-glucose, triglyceride, cholesterol of the intervention group were signifi- cantly lowethan those of the control group, buhigh- density lipoprotein wahighethan the control group. ConclusionStrengthening nursing intervention measurecan effectively control metabolisyndrome caused by Olanzapine treatment, which can improve the medication compliance of patientand prevenschizophrenirecurrence.
出处 《中国实用护理杂志》 北大核心 2013年第15期33-35,共3页 Chinese Journal of Practical Nursing
关键词 奥氮平 代谢综合征 护理干预 Olanzapine Metabolic syndrome Nursing intervention
  • 相关文献

参考文献6

二级参考文献30

  • 1郭珍,李春波,吴文源,李华芳,王克勋.利培酮及氯氮平对治疗精神分裂症患者血清Leptin浓度影响的初步研究[J].上海精神医学,2002,14(1):23-25. 被引量:5
  • 2Ilsernarie Kurzthaler. M. D. The clinical implication of weight gain in schizophrenia. J Clin Psychiatry,2001,62 (7) :32 - 37.
  • 3Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol : acute phase results of the North American doubleblind olanzapine trial [ J ]. Neuropsychopharmacology, 1996, 14(2) :111 - 123.
  • 4Green B. Focus on olanzapine[J]. Curr Med Res Opin, 1999,15(2) :79- 85.
  • 5Wirshing DA, Whirshing WC, Kusar L, et al. Novel antipsychotics: Comparison of weight gain liabilities[J ]. J Clin Psychiatry, 1999,60(6) : 358 - 363.
  • 6Wirshing DA,Spellberg BJ ,Erhart SM, et al. Novel antipsychotics and new onset diabetes[J]. Biol Psychiatry, 1998,44(8) : 778 -783.
  • 7Osser DN, Najarian DM, Dufresne RL, et al. Olartzapine increase weight and serum triglyceride levels[J]. J Clin Psychiatry, 1999,60( 11 ) : 767 - 770.
  • 8Kim HS, Kamboh MI. Genetic polymorphisms of apolipoproteins A -,E and H in Koreans. Hum Hered, 1998, 48(6): 313-317
  • 9Gushiken FC. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta2 - glycoprotein I. Am J Hematol, 2000, 65(2): 160- 165
  • 10Kamboh MI, Mehdi H. Genetics of apolipoprotein H(beta2-glycoprotein Ⅰ) and anionic phospholipid binding. Lupus, 1998, 7(suppl 2):S10 - S13

共引文献36

同被引文献153

引证文献12

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部